Vortex Therapeutics awarded an NIH Direct to Phase II award to advance IND-enabling studies of its first-in-class direct small molecule MYC inhibitor. Researchers at Vortex Therapeutics have been awarded a $2.2 Million grant from the National Institutes of Health (NIH) to advance the therapeutic development of their novel small molecule…

Northwestern University team led by Drs. Abdulkadir and Schiltz publish new research that defines that therapeutic effect of their small molecule MYC inhibitors on cancer cell metabolism. A research team at Northwestern University, led by Vortex Therapeutics founders Dr. Sarki Abdulkadir and Dr. Gary Schiltz, has published new findings that…

Vortex Therapeutics awarded first place in the 2023 Nucleate Venture Prize competition for its first-in-class MYC inhibitor. Vortex Therapeutics, a pioneering startup developing novel cancer therapies, has been awarded first place in the highly competitive 2023 Nucleate Venture Prize competition. The distinction was granted in recognition of the company’s groundbreaking…

Dr. Sarki Abdulkadir presents Vortex Therapeutics at the 3rd Annual Science2Startup (S2S)™ Dr. Sarki Abdulkadir, Founder of Vortex Therapeutics, recently presented the company’s pioneering work on its first-in-class MYC inhibitor at the 3rd Annual Science2Startup (S2S)™ showcase. The event, presented by Atlas Venture, F-Prime Capital, Osage University Partners, RA Capital…

Research team led by Vortex Therapeutics founders Drs. Sarki Abdulakdir and Gary Schiltz publish new work that describes the anti-tumor efficacy and mechanism of action of their first-in-class MYC inhibitors. A research team at Northwestern University, led by Vortex Therapeutics founders Dr. Sarki Abdulkadir and Dr. Gary Schiltz, has published…

Vortex Therapeutics founders Drs. Sarki Abdulkadir and Gary Schiltz publish groundbreaking research on the identification and characterization of the first orally bioavailable small molecule MYC inhibitor. Vortex Therapeutics today celebrated the publication of groundbreaking research by its founders, Dr. Sarki Abdulkadir and Dr. Gary Schiltz of Northwestern University, detailing the…